Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model
Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms
Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms